EG24206A - Crystalline composition containing escitalopram - Google Patents

Crystalline composition containing escitalopram

Info

Publication number
EG24206A
EG24206A EG2002070849A EG2002070849A EG24206A EG 24206 A EG24206 A EG 24206A EG 2002070849 A EG2002070849 A EG 2002070849A EG 2002070849 A EG2002070849 A EG 2002070849A EG 24206 A EG24206 A EG 24206A
Authority
EG
Egypt
Prior art keywords
composition containing
crystalline composition
containing escitalopram
escitalopram
crystalline
Prior art date
Application number
EG2002070849A
Other languages
English (en)
Inventor
Christensen V Troels
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of EG24206A publication Critical patent/EG24206A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG2002070849A 2001-07-31 2002-07-28 Crystalline composition containing escitalopram EG24206A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31

Publications (1)

Publication Number Publication Date
EG24206A true EG24206A (en) 2008-10-21

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002070849A EG24206A (en) 2001-07-31 2002-07-28 Crystalline composition containing escitalopram

Country Status (40)

Country Link
US (3) US6916941B2 (hr)
EP (2) EP1414435B1 (hr)
JP (4) JP2005525993A (hr)
KR (1) KR20040028947A (hr)
CN (2) CN1311819C (hr)
AR (1) AR034898A1 (hr)
AT (2) ATE286730T1 (hr)
AU (1) AU2002355624B2 (hr)
BG (1) BG108571A (hr)
BR (1) BR0206164A (hr)
CA (1) CA2451915C (hr)
CO (1) CO5560540A2 (hr)
CY (1) CY1106413T1 (hr)
DE (2) DE60217932T2 (hr)
DK (2) DK1414435T3 (hr)
EA (1) EA006213B1 (hr)
EG (1) EG24206A (hr)
ES (2) ES2280892T3 (hr)
HK (1) HK1070000A1 (hr)
HR (2) HRP20031073A2 (hr)
HU (1) HUP0401946A2 (hr)
IL (2) IL159326A0 (hr)
IS (1) IS7077A (hr)
MA (1) MA27349A1 (hr)
ME (1) MEP2108A (hr)
MX (1) MXPA04000849A (hr)
MY (1) MY126238A (hr)
NO (1) NO328346B1 (hr)
NZ (1) NZ530157A (hr)
PE (1) PE20030304A1 (hr)
PL (1) PL366995A1 (hr)
PT (2) PT1414435E (hr)
RS (1) RS8304A (hr)
SI (1) SI1414435T1 (hr)
TN (1) TNSN04021A1 (hr)
TR (1) TR200400189T2 (hr)
UA (1) UA79930C2 (hr)
UY (1) UY27404A1 (hr)
WO (1) WO2003011278A1 (hr)
ZA (1) ZA200309684B (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237604T1 (de) 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
DE60217932T2 (de) 2001-07-31 2007-08-30 H. Lundbeck A/S, Valby Kristalline Zusammensetzung enthaltend Escitalopram
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
CA2558198A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
WO2006123243A2 (en) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070098804A1 (en) * 2005-08-29 2007-05-03 Judith Aronhime Solid particulate tadalafil having a bimodal particle size distribution
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
US8252336B2 (en) 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
EP2291177A2 (en) * 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (hr) * 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CZ292911B6 (cs) * 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
PL199423B1 (pl) 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
ATE237604T1 (de) 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
DE60217932T2 (de) 2001-07-31 2007-08-30 H. Lundbeck A/S, Valby Kristalline Zusammensetzung enthaltend Escitalopram

Also Published As

Publication number Publication date
EP1522539A1 (en) 2005-04-13
ATE286730T1 (de) 2005-01-15
BG108571A (en) 2005-02-28
PL366995A1 (en) 2005-02-07
IS7077A (is) 2003-12-15
DK1522539T3 (da) 2007-05-07
NZ530157A (en) 2007-06-29
UY27404A1 (es) 2003-02-28
US20030212128A1 (en) 2003-11-13
TNSN04021A1 (en) 2006-06-01
CN1311819C (zh) 2007-04-25
DE60217932D1 (de) 2007-03-15
EP1522539B1 (en) 2007-01-24
HK1070000A1 (en) 2005-06-10
HRP20031073A2 (en) 2004-04-30
EP1414435B1 (en) 2005-01-12
AU2002355624B2 (en) 2006-02-02
ES2233842T3 (es) 2005-06-16
JP5192568B2 (ja) 2013-05-08
JP4971477B2 (ja) 2012-07-11
DE60217932T2 (de) 2007-08-30
BR0206164A (pt) 2003-10-28
RS8304A (en) 2006-12-15
HRPK20080410B3 (hr) 2009-09-30
DK1414435T3 (da) 2005-05-09
JP2012211186A (ja) 2012-11-01
DE60202615T2 (de) 2006-01-12
PT1522539E (pt) 2007-03-30
JP2005525993A (ja) 2005-09-02
ATE352546T1 (de) 2007-02-15
DE60202615D1 (de) 2005-02-17
IL159326A (en) 2010-05-31
JP5719811B2 (ja) 2015-05-20
EA200400243A1 (ru) 2004-06-24
PE20030304A1 (es) 2003-03-27
HRP20080410A2 (hr) 2008-10-31
SI1414435T1 (en) 2005-06-30
ES2280892T3 (es) 2007-09-16
CN1536997A (zh) 2004-10-13
WO2003011278A1 (en) 2003-02-13
TR200400189T2 (tr) 2004-12-21
CA2451915A1 (en) 2003-02-13
CA2451915C (en) 2010-09-21
US7420069B2 (en) 2008-09-02
EA006213B1 (ru) 2005-10-27
NO328346B1 (no) 2010-02-01
MY126238A (en) 2006-09-29
CO5560540A2 (es) 2005-09-30
NO20040380L (no) 2004-01-28
US6916941B2 (en) 2005-07-12
KR20040028947A (ko) 2004-04-03
EP1414435A1 (en) 2004-05-06
MEP2108A (xx) 2010-02-10
MXPA04000849A (es) 2004-05-14
CY1106413T1 (el) 2011-10-12
US20080305164A1 (en) 2008-12-11
UA79930C2 (en) 2007-08-10
ZA200309684B (en) 2004-12-22
MA27349A1 (fr) 2005-06-01
US20050147674A1 (en) 2005-07-07
CN1660074A (zh) 2005-08-31
PT1414435E (pt) 2005-05-31
HUP0401946A2 (hu) 2005-01-28
IL159326A0 (en) 2004-06-01
JP2011195591A (ja) 2011-10-06
JP2010150283A (ja) 2010-07-08
AR034898A1 (es) 2004-03-24

Similar Documents

Publication Publication Date Title
HK1070000A1 (en) Crystalline composition containing escitalopram
PL367134A1 (en) Novel composition
GB0114069D0 (en) Composition
GB0107651D0 (en) Composition
GB0122113D0 (en) Composition
EP1364646A4 (en) FENOFIBRATE CONTAINING COMPOSITION
GB0115679D0 (en) Composition
GB0130110D0 (en) Composition
GB0117305D0 (en) Composition
GB0126081D0 (en) Composition
GB0121454D0 (en) Composition
GB0126085D0 (en) Composition
GB0119470D0 (en) Novel composition
GB0119468D0 (en) Novel composition
GB0100458D0 (en) Novel composition
GB0108226D0 (en) Novel crystalline forms
GB0105325D0 (en) Composition
GB0112651D0 (en) Composition
GB0112688D0 (en) Composition
GB0113606D0 (en) Composition
GB0114067D0 (en) Composition
GB0112500D0 (en) Composition
GB0115076D0 (en) Composition
GB0105328D0 (en) Composition
GB0115939D0 (en) Composition